QR Code

Automated manufacturing of clinical-grade BDCA2 CAR NK cells in a closed system for the treatment of blastic plasmacytoid dendritic cell neoplasm

Recent progress in chimeric antigen receptor (CAR) natural killer (NK) cell therapy has demonstrated their promising potential in cancer immunotherapy. However, most current CAR NK cell manufacturing processes utilize open systems with multiple manual steps, making it challenging to maintain consist...

Full description

Saved in:
Main Authors: Rita Pfeifer, Sabine Müller, Marcus Nitsche, Melanie Sohmen, Julia Kostyra, Arthur Bister, Cathrin Bleilevens, Janina Brauner, Angela Mekes, Juliane Raasch, Dominika Lukas, Jens Kopatz, Wael Al Rawashdeh, Marsilius Mues, José Alberto Villacorta Hidalgo, Volker Huppert, Mario Assenmacher, Nina Möker, Rimas Orentas, Congcong Zhang
Format: Artigo
Language:Inglês
Published: Frontiers Media S.A. 2026-02-01
Series:Frontiers in Immunology
Subjects:
automated manufacturing
BDCA2 CAR
BPDCN
cancer immunotherapy
CAR NK cells
CliniMACS Prodigy NKCT
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2026.1761397/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items